BD and Techcyte Partner on AI-Based Application to Modernize Cervical Cancer Screening
FRANKLIN LAKES, N.J. & OREM, Utah – January 30, 2024 – Global medical technology leader BD (Becton, Dickinson and Company) has entered into a strategic collaboration with Techcyte, a pioneer in AI-powered diagnostic platforms. Together, they aim to launch an advanced AI-based application that brings digital efficiency and precision to Pap testing, enabling labs to better detect cervical cancer and precancerous lesions.
AI-Powered Cytology for Enhanced Accuracy and Efficiency
The new solution enables cervical cytology samples to be scanned, digitized, and analyzed using Techcyte’s AI algorithms, which prioritize and highlight abnormal cells for review. This digital application streamlines lab workflows and helps cytologists and pathologists focus on the most clinically relevant findings.
“This solution brings Pap testing into the digital age,” said Nikos Pavlidis, Acting President of Diagnostic Solutions at BD. “We’re addressing the global shortage of cytology professionals with an AI-powered tool that enhances accuracy and efficiency in cancer detection.”
Solving Clinical Workforce Gaps with Digital AI Tools
The platform supports labs facing increasing workloads and workforce shortages by minimizing manual interpretation variability. Integrated with the BD SurePath™ Liquid-based Pap Test and compatible with leading whole-slide scanners, the system allows remote review of samples through a secure digital environment.
Ben Cahoon, CEO of Techcyte, noted: “Our AI application helps cytotechnologists deliver more consistent, timely results by automatically identifying key diagnostic cells. This kind of tool is essential for maintaining quality care in modern labs.”
Advancing Cervical Cancer Detection on a Global Scale
While HPV screening is gaining prominence, Pap tests remain critical for detecting cellular changes linked to cancer progression. The BD–Techcyte AI application aims to support this dual approach, enabling faster intervention and improving clinical outcomes, especially during the global transition to next-gen screening standards.
Availability and Regulatory Pathway
The digital cytology solution is CE-marked for clinical use in Europe, and Techcyte is actively pursuing U.S. FDA approval and updated CE certification under IVDR. The offering will roll out across European markets in 2024, with U.S. availability following regulatory clearance.
By
